Patients who had larger body mass indexes BMIs greater than 35 lost even more weight, successfully shedding 85 pounds or 30.3% of their body weight after about two years
"Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel"
For patients who have experienced allodynia on semaglutide and then resume the medication or escalate to higher doses, closer monitoring for recurrence is advisable
Metabolic secondary outcomes included HbA1c, blood pressure (systolic and diastolic), HR, total cholesterol, triglycerides, hsCRP, HbA1c in participants with pre-existing pre-diabetes and T2D, blood pressure in participants with pre-existing hypertension and changes in T2D, and hypertension medication used in participants with T2D and hypertension, respectively
Understanding Your Semaglutide Dosage Plan can onboard pre-diabetic patients, and weve found that patients with a higher starting A1C level might need a higher dosage of semaglutide
